Shorter telomere length is associated with increased: Ovarian cancer risk in both familial and sporadic cases

Journal of Medical Genetics

Volumn 49, Issue 5, 2012, Pages 341-344

  Martinez Delgado, Beatriz ^a,b   Yanowsky, Kira ^a,b   Inglada Perez, Lucia ^a,b   de la Hoya, Miguel ^c   Caldes, Trinidad ^c   Vega, Ana ^b,d   Blanco, Ana ^b,d   Martin, Teresa ^e   Gonzalez Sarmiento, Rogelio ^f   Blasco, Maria ^a   Robledo, Mercedes ^a,b   Urioste, Miguel ^a,b   Song, Honglin ^g   Pharoah, Paul ^g   Benitez, Javier ^a,b  

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^c HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^d UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^e HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^f UNIVERSITY OF SALAMANCA   (Spain)

^g UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER RISK; CONTROLLED STUDY; FAMILIAL CANCER; FEMALE; GENE MUTATION; GROUPS BY AGE; HUMAN; HUMAN CELL; LEUKOCYTE; MAJOR CLINICAL STUDY; OVARY CANCER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; TELOMERE; TELOMERE LENGTH; TUMOR SUPPRESSOR GENE;

ADULT; CASE-CONTROL STUDIES; DNA; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LEUKOCYTES, MONONUCLEAR; LOGISTIC MODELS; MIDDLE AGED; OVARIAN NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; RISK FACTORS; SPAIN; TELOMERE; TELOMERE SHORTENING;

EID: 84864102809     PISSN: 00222593     EISSN: 14686244     Source Type: Journal    
DOI: 10.1136/jmedgenet-2012-100807     Document Type: Article

References (20)

1. Blasco MA. Telomeres and human disease: ageing, cancer and beyond. Nat Rev Genet 2005;6:611e22.
2. Calado RT, Young NS. Telomere diseases. N Engl J Med 2009;361:2353e65.
3. Vulliamy TJ, Marrone A, Knight SW, Walne A, Mason PJ, Dokal I. Mutations in dyskeratosis congenita: their impact on telomere length and the diversity of clinical presentation. Blood 2006;107:2680e5.
4. Allsopp RC, Vaziri H, Patterson C, Goldstein S, Younglai EV, Futcher AB, Greider CW, Harley CB. Telomere length predicts replicative capacity of human fibroblasts. Proc Natl Acad Sci U S A 1992;89:10114e18.
5. Wu X, Amos CI, Zhu Y, Zhao H, Grossman BH, Shay JW, Luo S, Hong WK, Spitz MR. Telomere dysfunction: a potential cancer predisposition factor. J Natl Cancer Inst 2003;95:1211e18.
6. Broberg K, Bjork J, Paulsson K, Hoglund M, Albin M. Constitutional short telomeres are strong genetic susceptibility markers for bladder cancer. Carcinogenesis 2005;26:1263e71.
7. Jang JS, Choi YY, Lee WK, Choi JE, Cha SI, Kim YJ, Kim CH, Kam S, Jung TH, Park JY. Telomere length and the risk of lung cancer. Cancer Sci 2008; 99:1385e9.
8. Hou L, Savage SA, Blaser MJ, Perez-Perez G, Hoxha M, Dioni L, Pegoraro V, Dong LM, Zatonski W, Lissowska J, Chow WH, Baccarelli A. Telomere length in peripheral leukocyte DNA and gastric cancer risk. Cancer Epidemiol Biomarkers Prev 2009;18:3103e9.
9. Pooley KA, Sandhu MS, Tyrer J, Shah M, Driver KE, Luben RN, Bingham SA, Ponder BA, Pharoah PD, Khaw KT, Easton DF, Dunning AM. Telomere length in prospective and retrospective cancer case-control studies. Cancer Res 2010;70:3170e6.
10. Wang SJ, Sakamoto T, Yasuda Si S, Fukasawa I, Ota Y, Hayashi M, Okura T, Zheng JH, Inaba N. The relationship between telomere length and telomerase activity in gynecologic cancers. Gynecol Oncol 2002;84:81e4.
11. Idei T, Sakamoto H, Yamamoto T. Terminal restriction fragments of telomere are detectable in plasma and their length correlates with clinical status of ovarian cancer patients. J Int Med Res 2002;30:244e50.
12. Mirabello L, Garcia-Closas M, Cawthon R, Lissowska J, Brinton LA, Peplonska B, Sherman ME, Savage SA. Leukocyte telomere length in a population-based casecontrol study of ovarian cancer: a pilot study. Cancer Causes Control 2010;21:77e82.
13. Terry KL, Tworoger SS, Vitonis AF, Wong J, Titus-Ernstoff L, De Vivo I, Cramer DW. Telomere length and genetic variation in telomere maintenance genes in relation to ovarian cancer risk. Cancer Epidemiol Biomarkers Prev 2012;21:504e12.
14. Martinez-Delgado B, Yanowsky K, Inglada-Perez L, Domingo S, Urioste M, Osorio A, Benitez J. Genetic anticipation is associated with telomere shortening in hereditary breast cancer. PLoS Genet 2011;7:e1002182.
15. Badie S, Escandell JM, Bouwman P, Carlos AR, Thanasoula M, Gallardo MM, Suram A, Jaco I, Benitez J, Herbig U, Blasco MA, Jonkers J, Tarsounas M. BRCA2 acts as a RAD51 loader to facilitate telomere replication and capping. Nat Struct Mol Biol 2010;17:1461e9.
16. Song H, Ramus SJ, Quaye L, DiCioccio RA, Tyrer J, Lomas E, Shadforth D, Hogdall E, Hogdall C, McGuire V, Whittemore AS, Easton DF, Ponder BA, Kjaer SK, Pharoah PD, Gayther SA. Common variants in mismatch repair genes and risk of invasive ovarian cancer. Carcinogenesis 2006;27:2235e42.
17. Wentzensen IM, Mirabello L, Pfeiffer RM, Savage SA. The association of telomere length and cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2011;20:1238e50.
18. Kim S, Parks CG, DeRoo LA, Chen H, Taylor JA, Cawthon RM, Sandler DP. Obesity and weight gain in adulthood and telomere length. Cancer Epidemiol Biomarkers Prev 2009;18:816e20.
19. Lynch HT, Casey MJ, Snyder CL, Bewtra C, Lynch JF, Butts M, Godwin AK. Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management. Mol Oncol 2009;3:97e137.
20. De Vivo I, Prescott J, Wong JY, Kraft P, Hankinson SE, Hunter DJ. A prospective study of relative telomere length and postmenopausal breast cancer risk. Cancer Epidemiol Biomarkers Prev 2009;18:1152e6.